Navigation Links
Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
Date:10/22/2007

TAXUS ATLAS studies also reinforce deliverability of TAXUS(R) Liberte(R)

drug-eluting stent in long lesions and small vessels

NATICK, Mass. and WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month data from the pivotal TAXUS ATLAS Small Vessel and Long Lesion studies, which evaluate the TAXUS(R) Liberte(R) Paclitaxel-Eluting Stent System in complex lesions. The TAXUS Liberte 2.25 mm Stent significantly reduced restenosis and maintained or improved safety outcomes compared to the already highly effective first- generation TAXUS Express(TM) Stent, which has been used in more than four million implants since 2003 and has been the benchmark against which many newer stents have been compared. The TAXUS Liberte Long (38 mm) Stent showed further significant reduction in the incidence of Non-Q-Wave Myocardial Infarction (MI, or heart attack) occurring at the time of the procedure compared to the earlier generation TAXUS stent. The data also demonstrated enhanced deliverability for both the TAXUS Liberte 2.25 mm Stent and for the TAXUS Liberte Long Stent.

The results were presented by Mark A. Turco, M.D., Director of the Center for Cardiac and Vascular Research, Washington Adventist Hospital, and co- principal investigator of the trial, at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

"The TAXUS ATLAS studies show the TAXUS Liberte Stent to be highly deliverable in complex lesions, while significantly reducing restenosis in small vessels," said Dr. Turco. "The positive data from the TAXUS ATLAS studies suggest that improvements in
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
3. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
4. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
5. To Stent or Not: Is That the Question?
6. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
9. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
11. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Markets to 2020 - Novel Therapeutic ... Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics in ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... to 2020 - Broadened Diagnostic Criteria ... Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 - ...
(Date:8/28/2014)... , Aug. 28, 2014  Rx Safes, Inc., ... announced that it is waging a new war on ... national media campaign. More than 2,500 children ... time and these drugs are easily accessed from unsecured medicine ... drug dealers on the streets, Rx Safes will address ...
Breaking Medicine Technology:Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Rx Safes, Inc. Announces New War On Drugs 2
(Date:8/28/2014)... these particular arguments against the policy, put forward by ... the first country in the world to introduce standardised ... Ireland, and the UK are currently considering similar legislation. ... policy would deter people from buying their tobacco from ... of cheap products sourced from Asia, and increase the ...
(Date:8/28/2014)... of women who are given information about the chance ... not fully understand the risks involved, according to research ... , today (Friday). , In a survey of around ... London (UCL) found that 64 per cent felt they ... chance that screening will pick up cancers that would ...
(Date:8/28/2014)... Millennium Treatment Group recently announced a new goal. ... Millennium Treatment Group is working to close it, providing more ... According to the National Survey on Drug Use and ... have benefited from treatment for drug and/or substance abuse, but ... that there is a large treatment gap in the United ...
(Date:8/28/2014)... Aug. 28, 2014 (HealthDay News) -- Arguments between parents ... study indicates. Parents in more than 200 families ... days. At the end of each day, mothers and ... relationship with their children. On days when parents ... with their children were also strained, according to the ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 ... bellwether trial of a transvaginal mesh lawsuit ( ... Inc., Bernstein Liebhard LLP reports. Court documents pending ... West Virginia indicate that the case was filed ... undergo two revision surgeries, allegedly due to vaginal ...
Breaking Medicine News(10 mins):Health News:Plain cigarette packs don't hurt small retailers or boost trade in illicit tobacco 2Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Kids Dental July 1, LANSING, Mich., June 12 ... of Community Health (MDCH) today,announced an expansion of the ... Genesee and Saginaw counties, bringing the total,number of Michigan ... effect July 1, 2008., "We are extending needed ...
... anticancer drug sensitivity found in translation , The ... large problem. In some cases, such resistance is associated ... translation, which is central to the generation of proteins. ... McGill University, Montreal, have identified a drug that can ...
... June 12 MEDRAD, INC., has signed ... Solutions,a fully owned subsidiary of Siemens Medical ... care providers to inject Fluorodeoxyglucose,(FDG) for Positron ... innovative, new way. The partnership will leverage,MEDRAD,s ...
... molecular machinery is pointing toward new drugs and treatments ... era of personalized medicine, in which doctors aim to ... the right patient, also brings concerns about genetic privacy, ... , The American Association for the Advancement of Science ...
... Protection Act Will End Pre-Existing Condition,Limitations For Children ... Conditions, WASHINGTON, June 12 The National ... dedicated,to the mission of creating avenues of improved ... at the state and federal levels -- today,praised ...
... to track down source of salmonella-contaminated tomatoes , , ... ongoing outbreak of salmonella-contaminated tomatoes as a backdrop, ... and Drug Administration has failed to meet its ... supply. , Investigators for the Government Accountability Office ...
Cached Medicine News:Health News:Dental Services Expand to Serve More Than 280,000 Michigan Children 2Health News:JCI online early table of contents: June 12, 2008 2Health News:JCI online early table of contents: June 12, 2008 3Health News:JCI online early table of contents: June 12, 2008 4Health News:JCI online early table of contents: June 12, 2008 5Health News:JCI online early table of contents: June 12, 2008 6Health News:JCI online early table of contents: June 12, 2008 7Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 3Health News:AAAS hosts June 20 conference on personalized medicine 2Health News:National Patient Advocate Foundation Applauds Senators Lautenberg and Brown for Protecting Health Care Coverage for At-Risk Children 2Health News:National Patient Advocate Foundation Applauds Senators Lautenberg and Brown for Protecting Health Care Coverage for At-Risk Children 3Health News:Congressional Report Criticizes FDA for Food Safety 2Health News:Congressional Report Criticizes FDA for Food Safety 3Health News:Congressional Report Criticizes FDA for Food Safety 4Health News:Congressional Report Criticizes FDA for Food Safety 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: